- Home
- BOLT vs IMRN Comparison
BOLT vs IMRN Comparison
Compare BOLT & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BOLT
- IMRN
- Stock Information
- Founded
- BOLT 2015
- IMRN 1994
- Country
- BOLT United States
- IMRN Australia
- Employees
- BOLT N/A
- IMRN N/A
- Industry
- BOLT Biotechnology: Pharmaceutical Preparations
- IMRN Biotechnology: Pharmaceutical Preparations
- Sector
- BOLT Health Care
- IMRN Health Care
- Exchange
- BOLT Nasdaq
- IMRN Nasdaq
- Market Cap
- BOLT 9.4M
- IMRN 9.2M
- IPO Year
- BOLT 2021
- IMRN N/A
- Fundamental
- Price
- BOLT $5.32
- IMRN $1.86
- Analyst Decision
- BOLT Buy
- IMRN Strong Buy
- Analyst Count
- BOLT 3
- IMRN 1
- Target Price
- BOLT $47.50
- IMRN $5.00
- AVG Volume (30 Days)
- BOLT 10.9K
- IMRN 45.6K
- Earning Date
- BOLT 11-11-2025
- IMRN 08-29-2025
- Dividend Yield
- BOLT N/A
- IMRN N/A
- EPS Growth
- BOLT N/A
- IMRN N/A
- EPS
- BOLT N/A
- IMRN N/A
- Revenue
- BOLT $4,167,000.00
- IMRN $4,777,422.00
- Revenue This Year
- BOLT N/A
- IMRN N/A
- Revenue Next Year
- BOLT N/A
- IMRN N/A
- P/E Ratio
- BOLT N/A
- IMRN N/A
- Revenue Growth
- BOLT N/A
- IMRN 48.63
- 52 Week Low
- BOLT $4.59
- IMRN $1.50
- 52 Week High
- BOLT $14.36
- IMRN $2.87
- Technical
- Relative Strength Index (RSI)
- BOLT 51.15
- IMRN 53.28
- Support Level
- BOLT $5.00
- IMRN $1.80
- Resistance Level
- BOLT $5.50
- IMRN $1.94
- Average True Range (ATR)
- BOLT 0.22
- IMRN 0.07
- MACD
- BOLT 0.05
- IMRN 0.00
- Stochastic Oscillator
- BOLT 74.06
- IMRN 61.72
About BOLT Bolt Biotherapeutics Inc.
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.
About IMRN Immuron Limited
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.